Percepta® Nasal Swab
PERCEPTA® NASAL SWAB
What is the test?
Objective tools are needed to assess the risk of lung cancer in patients with detected lung nodules
What is Percepta Nasal Swab?
It is a first-of-its-kind, office-based genomic test that objectively classifies lung cancer risk in an identified lung nodule of patients that are ever-smokers. The test result can provide guidance on which patients can safely avoid unnecessary invasive procedures or undergo further workup to confirm their diagnosis.
Percepta Nasal Swab uses a simple and convenient nasal brushing to objectively evaluate suspicious lung nodules
A simple nasal swab brushing just past the inferior nasal turbinate is used to collect a sample, which is sent to Veracyte.
Monitor with low dose CT
Consider non-surgical tissue sampling inclusive of bronchoscopy
Consider sending patients for direct surgery and/or treatment
NIGHTINGALE Study to demonstrate clinical utility of the Percepta Nasal Swab test in management of patients with lung nodules
- Multicenter, randomized, prospective, observational clinical trial
- Included populations:
– Newly identified nodule ≤30mm on CT or LDCT
– Current or former smoker (≥100 cigarettes in a lifetime)
– 29-85 years of age
– No known active cancer or prior history of lung cancer
- – Newly identified nodule ≤30mm on CT or LDCT
- – Current or former smoker (≥100 cigarettes in a lifetime)
- – 29-85 years of age
- – No known active cancer or prior history of lung cancer
Help shape the future of lung nodule management by participating in our clinical trials. Contact us to learn more!
Percepta Nasal Swab Evidence
CHEST 2021 Abstract
This Veracyte abstract presented at CHEST 2021 demonstrated how the nasal classifier accurately assesses ROM in a pulmonary nodule independent of size or stage. Use of the classifier to guide decision-making for ever-smokers with a lung nodule could lead to fewer unnecessary diagnostic procedures in patients without cancer and timelier treatment in patients with lung cancer.
ATS 2022 Poster
This Veracyte Poster presented at ATS 2022 demonstrated how the nasal classifier accurately assesses cancer risk in pulmonary nodules across the spectrum of tobacco-related lung cancer risk, with similar performance in those who meet USPSTF screening criteria for high risk of lung cancer and those who do not. The nasal classifier has good performance in patients independent of stratification by smoking burden, with 100% sensitivity for the low –risk label in lighter smokers.